Unicycive Therapeutics, Inc. 8-K

What Happened

• Unicycive Therapeutics, Inc. filed a Form 8-K on April 6, 2026 (Item 5.02) announcing that director Gaurav Aggarwal resigned from the Company’s Board of Directors effective April 6, 2026.
• The filing states Dr. Aggarwal’s resignation was not due to any disagreement with the Company, its management, or the Board. The Company thanked him for his service.

Key Details

• Filing type: Form 8-K, Item 5.02 (Departure/Election of Directors or Certain Officers).
• Effective date of resignation: April 6, 2026.
• Director: Gaurav Aggarwal — resignation not related to any disagreement with company operations, policies, or practices.
• Company response: expressed gratitude for Dr. Aggarwal’s service on the Board.

Why It Matters

• A director resignation changes board composition and could affect governance and oversight, so investors should note the departure.
• Because the company explicitly disavowed any disagreement, the filing does not indicate internal conflict or immediate operational issues.
• Investors may watch for follow-up filings about any replacement director or board changes that could affect corporate strategy or oversight.